Clinical trials: Head and Neck Cancers- Squamous Cell
Carcinoma, Squamous Cell of the Head and Neck
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN® therapeutic reovirus in combination with Paclitaxel and Carboplatin is effective and safe in the treatment of squamous cell…
- Trial name
- NCT00753038
- Testing
- REOLYSIN®, Carboplatin, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Oncolytics Biotech
Head and Neck Squamous Cell Carcinoma
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent…
- Trial name
- NCT06496178
- Testing
- Petosemtamab, Investigator's Choice
- Where
- 193 sites in United States, Argentina and 22 more
- Volunteers
- 621 people
- Sponsor
- Genmab
Locally Advanced Head and Neck Squamous Cell Carcinoma
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
The goal of this prospective, randomized, single-blind controlled clinical study is to explore the efficacy of maintenance therapy with Sintilimab after chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.
- Trial name
- NCT06240689
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
This phase II trial is studying how well cediranib maleate works in treating patients with recurrent or newly diagnosed metastatic head and neck cancer.
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT00458978
- Testing
- Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
- Trial name
- NCT06953089
- Testing
- DB-1311/BNT324, BNT327, DB-1305/BNT325
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 750 people
- Sponsor
- DualityBio Inc.
HNSCC, Head and Neck Neoplasms
A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy
Open, multicenter, single arm, phase II, biomarker driven umbrella trial for head and neck squamous cell carcinoma (FGFR inhibitor, CDK4/6 inhibitor, pan HER inhibitor, PI3K inhibitor, PD1/PD-L1 inhibitor)
- Trial name
- NCT03356587
- Testing
- Abemaciclib
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Seoul National University Hospital
Head and Neck Squamous Cell Cancer
Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer
This study is a multicenter phase Ⅲ trial. The objective is to compare the efficacy and toxicity of cisplatin plus raltitrexed or 5-fluorouracil in concurrence with IMRT for patients with locoregionally advanced head and neck…
- Trial name
- NCT02485548
- Testing
- Raltitrexed, 5-fluorouracil, Cisplatin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Head and Neck Squamous Cell Carcinoma
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
Master protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies.
- Trial name
- VELOCITY-HNSCC (NCT06727565)
- Testing
- Domvanalimab, Zimberelimab, Paclitaxel
- Where
- 23 sites in United States, Australia and 7 more
- Volunteers
- 39 people
- Sponsor
- Gilead Sciences
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Skin Melanoma, Squamous Non-small-cell Lung Cancer
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
The goal of this double-blind, randomized study is to establish the equivalence of pharmacokinetic properties, as well as the comparability of safety, immunogenicity and pharmacodynamics of the drug RPH-075 (international…
- Conditions
- Skin Melanoma, Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06307093
- Testing
- RPH-075, Keytruda®
- Where
- 23 sites in Russia
- Volunteers
- 90 people
- Sponsor
- R-Pharm
Esophageal Squamous Cell Carcinoma
Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
This is a prospective, single-center, single-arm Phase II clinical study designed to evaluate the efficacy and safety of sacituzumab tirumotecan in combination with tislelizumab in patients with advanced esophageal squamous cell…
- Trial name
- NCT07811752
- Testing
- Sacituzumab Tirumotecan (SKB264) plus Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Shanghai Chest Hospital
Locally Advanced Esophageal Carcinoma
Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus
Adding PD-1 inhibitors to neoadjuvant chemoradiotherapy has shown promising results in locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- SCALE-2 (NCT05424432)
- Testing
- Neoadjuvant Chemotherapy, Neoadjuvant Toripalimab, Short Course Neoadjuvant Radiotherapy
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC
This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of neoadjuvant low-dose radiotherapy combined with chemoimmunotherapy in resectable locally advanced head and neck squamous cell…
- Trial name
- NCT05343325
- Testing
- Tislelizumab, Low-dose radiotherapy
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Squamous Cell Carcinoma, Oropharyngeal Cancers
Oral Mucositis Management in Patients Receiving Radiation for Head and Neck Cancer: An Evaluation of a Barrier Based Treatment
Patients who are undergoing radiation therapy on their head and/or neck, are highly likely to experience oral mucositis, which is inflammation and irritation of the mucus membranes in your mouth.
- Conditions
- Squamous Cell Carcinoma, Oropharyngeal Cancers, Nasopharyngeal Cancer, Hypopharyngeal Cancer
- Trial name
- TOPHAT (NCT07697287)
- Testing
- Gelclair Oral Mouth Rinse
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- McMaster University
Primary Advanced Carcinoma of the Oral Cavity or Oropharynx, Squamous Cell Carcinoma of the Head and Neck
Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor
The primary goal of this study is to determine if the vaccine can be safely given to subjects, and to see what side effects occur (both good and bad) when they are given this experimental tumor vaccine.
- Trial name
- NCT00377247
- Testing
- autologous monocyte-derived dendritic cells (DC) transfected with DNA
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pittsburgh
Esophageal Squamous Cell Carcinoma
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma
This is a open-label, multicenter study to assess the safety, tolerability, and preliminary efficacy of IPM514 in patients with esophageal squamous cell carcinoma.
- Trial name
- NCT06690476
- Testing
- Dose escalation(IPM514 monotherapy), Dose expansion (IPM514 combined with tislelizumab), Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Peking University
Head and Neck Cancer
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00281840
- Testing
- bevacizumab, docetaxel, conventional surgery
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Squamous Cell Carcinoma, Human Papilloma Virus (HPV)
Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)
This single-arm Phase II trial evaluates whether omission of postoperative radiotherapy is feasible and oncologically safe in select patients with HPV-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC).
- Conditions
- Squamous Cell Carcinoma, Human Papilloma Virus (HPV), Oropharyngeal Squamous Cell Carcinoma (OPSCC)
- Trial name
- NCT07513389
- Testing
- Active Surveillance With ctHPVDNA (NavDx®)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical University of South Carolina
Head and Neck Squamous Cell Carcinoma
2B or Not 2B? Shoulder Function After Level 2B Neck Dissection: A Randomized Controlled Study
Many types of head and neck cancers will have local spread to the neck. As such selective neck dissection is performed as part of the treatment. The neck is divided into various levels.
- Trial name
- 2BN2B (NCT00765791)
- Testing
- Selective Neck Dissection Excluding Level 2B, Selective Neck Dissection Including Level 2B
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Alberta
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.